Capsule Summary Slides

Share

Program Content

Activities

  • ATTRACTION-5
    ATTRACTION-5: Phase III Study of Adjuvant Nivolumab + Chemotherapy After Gastrectomy for Pathologic Stage III Gastric or Gastroesophageal Junction Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2023

  • NORPACT-1
    NORPACT-1: Neoadjuvant FOLFIRINOX vs Upfront Surgery in Resectable Pancreatic Head Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2023

  • KEYNOTE-966 HRQoL
    KEYNOTE-966: Health-Related Quality-of-Life Outcomes With Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy in Advanced Biliary Tract Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2023

  • Zanidatamab for HER2+ BTC
    HERIZON-BTC-01: Zanidatamab, a HER2-Targeted Bispecific Antibody, in Previously Treated HER2‑Amplified Biliary Tract Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2023

  • Tucatinib + Trastuzumab in HER2+ BTC
    Tucatinib + Trastuzumab for Previously Treated Advanced HER2+ Biliary Tract Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2023

  • AtezoTRIBE Update
    AtezoTRIBE: Updated Results of First-line Treatment With FOLFOXIRI + Bevacizumab ± Atezolizumab for Unresectable Metastatic Colorectal Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2023

  • PROSPECT
    PROSPECT: Neoadjuvant Chemoradiation vs FOLFOX With Selective Chemoradiation for Locally Advanced Rectal Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2023

  • FIRE-4 Liquid Biopsy Analysis
    FIRE-4: RAS/BRAF Mutation by Liquid Biopsy and Benefit From First-line FOLFIRI + Cetuximab in Patients With RAS-WT Metastatic Colorectal Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from Merck Sharp & Dohme Corp., Novocure, and Seagen.

Merck Sharp & Dohme Corp.

Novocure

Seagen